Ablation of the decorin gene enhances experimental hepatic fibrosis and impairs hepatic healing in mice

Laboratory Investigation

Volumn 91, Issue 3, 2011, Pages 439-451

  Baghy, Kornélia ^a   Dezso, Katalin ^a   László, Viktória ^a   Fullár, Alexandra ^a   Péterfia, Bálint ^a   Paku, Sándor ^a   Nagy, Péter ^a   Schaff, Zsuzsa ^a   Iozzo, Renato V ^b   Kovalszky, Ilona ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

decorin; Erk1 2; liver fibrosis; MMP 2; MMP 9; TGF 1

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 4; DECORIN; GELATINASE; GELATINASE A; GELATINASE B; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMAD2 PROTEIN; SMAD3 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CONNECTIVE TISSUE; CONTROLLED STUDY; DECORIN GENE; DISEASE SEVERITY; ENZYMATIC ASSAY; FEMALE; GENE; GENOTYPE; HEALING; LIVER FIBROSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; UPREGULATION; WILD TYPE;

EID: 79952096565     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2010.172     Document Type: Article

References (65)

1. Hope TA, Herfkens RJ, Denianke KS, et al. Nephrogenic systemic fibrosis in patients with chronic kidney disease who received gadopentetate dimeglumine. Invest Radiol 2009;44:135-139.
2. Zois CD, Baltayiannis GH, Karayiannis P, et al. Systematic review: hepatic fibrosis-regression with therapy. Aliment Pharmacol Ther 2008;28:1175-1187.
3. Calvaruso V, Maimone S, Gatt A, et al. Coagulation and fibrosis in chronic liver disease. Gut 2008;57:1722-1727.
4. Schnaper HW. Balance between matrix synthesis and degradation: a determinant of glomerulosclerosis. Pediatr Nephrol 1995;9:104-111.
5. Balsano C, Alisi A, Nobili V. Liver fibrosis and therapeutic strategies: the goal for improving metabolism. Curr Drug Targets 2009;10:505-512.
6. Epple A, Kuhn HA, Leveringhaus M, et al. Etiology, complications and prognosis of liver cirrhosis in 917 patients. II. Causes of death and prognosis in liver cirrhosis. Lebensversicher Med 1979;31:117-122. (Pubitemid 10227939)
7. Fartoux L, Serfaty L. Liver cirrhosis in adults: etiology and specific treatments. Rev Prat 2005;55:1539-1548. (Pubitemid 41404878)
8. Friedman SL. Liver fibrosis-from bench to bedside. J Hepatol 2003;38(Suppl 1):S38-S53.
9. Kato I, Tominaga S, Ikari A. The risk and predictive factors for developing liver cancer among patients with decompensated liver cirrhosis. Jpn J Clin Oncol 1992;22:278-285.
10. La Vecchia C, Negri E, Cavalieri d'Oro L, et al. Liver cirrhosis and the risk of primary liver cancer. Eur J Cancer Prev 1998;7:315-320. (Pubitemid 28473983)
11. Albillos Martinez A. What is the treatment of choice in a patient with liver cirrhosis and esophageal varices that have bled to prevent rebleeding: beta-blockers, endoscopic ligation or both?. Gastroenterol Hepatol 2009;32:124-125.
12. Garcia-Tsao G, Lim J. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol 2009;104:1802-1829.
13. Vallet-Pichard A, Mallet V, Costentin CE, et al. Treatment of HBV-related cirrhosis. Expert Rev Anti Infect Ther 2009;7:527-535.
14. Schmidt A, Lorkowski S, Seidler D, et al. TGF-beta1 generates a specific multicomponent extracellular matrix in human coronary SMC. Eur J Clin Invest 2006;36:473-482. (Pubitemid 43876127)
15. De Bleser PJ, Niki T, Rogiers V, et al. Transforming growth factor-beta gene expression in normal and fibrotic rat liver. J Hepatol 1997;26: 886-893. (Pubitemid 27145714)
16. Gauldie J, Bonniaud P, Sime P, et al. TGF-beta, Smad3 and the process of progressive fibrosis. Biochem Soc Trans 2007;35:661-664. (Pubitemid 47310335)
17. Kanzler S, Lohse AW, Keil A, et al. TGF-beta1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am J Physiol 1999;276:G1059-G1068. (Pubitemid 29214121)
18. Wang H, Mengsteab S, Tag CG, et al. Transforming growth factor-beta1 gene polymorphisms are associated with progression of liver fibrosis in Caucasians with chronic hepatitis C infection. World J Gastroenterol 2005;11:1929-1936. (Pubitemid 40520988)
19. Shek FW, Benyon RC. How can transforming growth factor beta be targeted usefully to combat liver fibrosis? Eur J Gastroenterol Hepatol 2004;16:123-126. (Pubitemid 39049646)
20. Iozzo RV. The biology of the small leucine-rich proteoglycans. Functional network of interactive proteins. J Biol Chem 1999;274: 18843-18846. (Pubitemid 29314072)
21. Schaefer L, Iozzo RV. Biological functions of the small leucine-rich proteoglycans: from genetics to signal transduction. J Biol Chem 2008;283:21305-21309.
22. Ameye L, Young MF. Mice deficient in small leucine-rich proteoglycans: novel in vivo models for osteoporosis, osteoarthritis, Ehlers-Danlos syndrome, muscular dystrophy, and corneal diseases. Glycobiology 2002;12:107R-116R.
23. Yamaguchi Y, Mann DM, Ruoslahti E. Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 1990; 346:281-284.
24. Zhang Z, Li XJ, Liu Y, et al. Recombinant human decorin inhibits cell proliferation and downregulates TGF-beta1 production in hypertrophic scar fibroblasts. Burns 2007;33:634-641. (Pubitemid 46880036)
25. Isaka Y, Brees DK, Ikegaya K, et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 1996;2:418-423. (Pubitemid 26191913)
26. Dudas J, Kovalszky I, Gallai M, et al. Expression of decorin, transforming growth factor-beta 1, tissue inhibitor metalloproteinase 1 and 2, and type IV collagenases in chronic hepatitis. Am J Clin Pathol 2001;115:725-735. (Pubitemid 33051540)
27. Weber IT, Harrison RW, Iozzo RV. Model structure of decorin and implications for collagen fibrillogenesis. J Biol Chem 1996;271: 31767-31770. (Pubitemid 26422189)
28. Zhang G, Ezura Y, Chervoneva I, et al. Decorin regulates assembly of collagen fibrils and acquisition of biomechanical properties during tendon development. J Cell Biochem 2006;98:1436-1449. (Pubitemid 44141849)
29. Danielson KG, Baribault H, Holmes DF, et al. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J Cell Biol 1997;136:729-743. (Pubitemid 27083772)
30. Santra M, Reed CC, Iozzo RV. Decorin binds to a narrow region of the epidermal growth factor (EGF) receptor, partially overlapping but distinct from the EGF-binding epitope. J Biol Chem 2002;277 :35671-35681.
31. Reed CC, Gauldie J, Iozzo RV. Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin. Oncogene 2002;21: 3688-3695. (Pubitemid 34620532)
32. Csordas G, Santra M, Reed CC, et al. Sustained down-regulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumor growth in vivo. J Biol Chem 2000;275:32879-32887.
33. Fiedler LR, Schonherr E, Waddington R, et al. Decorin regulates endothelial cell motility on collagen I through activation of insulin-like growth factor I receptor and modulation of alpha2beta1 integrin activity. J Biol Chem 2008;283:17406-17415.
34. Goldoni S, Humphries A, Nystrom A, et al. Decorin is a novel antagonistic ligand of the Met receptor. J Cell Biol 2009;185: 743-754.
35. Schaefer L, Tsalastra W, Babelova A, et al. Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-I receptor and mammalian target of rapamycin. Am J Pathol 2007;170:301-315. (Pubitemid 47339209)
36. Schönherr E, Sunderkotter C, Iozzo RV, et al. Decorin, a novel player in the insulin-like growth factor system. J Biol Chem 2005;280: 15767-15772. (Pubitemid 40616696)
37. Merline R, Lazaroski S, Babelova A, et al. Decorin deficiency in diabetic mice: aggravation of nephropathy due to overexpression of profibrotic factors, enhanced apoptosis and mononuclear cell infiltration. J Physiol Pharmacol 2009;60(Suppl 4):5-13.
38. Xu L, Hui AY, Albanis E, et al. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 2005;54:142-151. (Pubitemid 40007234)
39. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
40. Woessner Jr JF. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 1961;93:440-447.
41. Fels IG. Determination of hydroxyproline in liver. Clin Chem 1958;4:62-65.
42. Clouthier DE, Comerford SA, Hammer RE. Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like syndrome in PEPCK-TGFbeta1 transgenic mice. J Clin Invest 1997;100:2697-2713. (Pubitemid 28007537)
43. El-Gamel A, Awad MR, Hasleton PS, et al. Transforming growth factorbeta (TGF-beta1) genotype and lung allograft fibrosis. J Heart Lung Transplant 1999;18:517-523. (Pubitemid 29291657)
44. Huijun W, Long C, Zhigang Z, et al. Ex vivo transfer of the decorin gene into rat glomerulus via a mesangial cell vector suppressed extracellular matrix accumulation in experimental glomerulonephritis. Exp Mol Pathol 2005;78:17-24. (Pubitemid 41373312)
45. Droguett R, Cabello-Verrugio C, Riquelme C, et al. Extracellular proteoglycans modify TGF-beta bio-availability attenuating its signaling during skeletal muscle differentiation. Matrix Biol 2006;25: 332-341. (Pubitemid 44202585)
46. Fischer JW, Kinsella MG, Levkau B, et al. Retroviral overexpression of decorin differentially affects the response of arterial smooth muscle cells to growth factors. Arterioscler Thromb Vasc Biol 2001;21:777-784. (Pubitemid 32448768)
47. Kahari VM, Larjava H, Uitto J. Differential regulation of extracellular matrix proteoglycan (PG) gene expression. Transforming growth factor-beta 1 up-regulates biglycan (PGI), and versican (large fibroblast PG) but down-regulates decorin (PGII) mRNA levels in human fibroblasts in culture. J Biol Chem 1991;266:10608-10615. (Pubitemid 21906845)
48. Breitkopf K, Haas S, Wiercinska E, et al. Anti-TGF-beta strategies for the treatment of chronic liver disease. Alcohol Clin Exp Res 2005;29: 121S-131S. (Pubitemid 43194338)
49. Shi YF, Zhang Q, Cheung PY, et al. Effects of rhDecorin on TGF-beta1 induced human hepatic stellate cells LX-2 activation. Biochim Biophys Acta 2006;1760:1587-1595. (Pubitemid 44679805)
50. Dong FQ, Li H, Wu F, et al. [Effects of overexpression of decorin on matrix metalloproteinases 2 and 9 in rat mesangial and tubular cells]. Zhonghua Yi Xue Za Zhi 2008;88:3444-3447.
51. Al Haj Zen A, Lafont A, Durand E, et al. Effect of adenovirus-mediated overexpression of decorin on metalloproteinases, tissue inhibitors of metalloproteinases and cytokines secretion by human gingival fibroblasts. Matrix Biol 2003;22:251-258. (Pubitemid 36802367)
52. Akool el S, Doller A, Muller R, et al. Nitric oxide induces TIMP-1 expression by activating the transforming growth factor beta-Smad signaling pathway. J Biol Chem. 2005;280:39403-39416. (Pubitemid 41713898)
53. Kutz SM, Hordines J, McKeown-Longo PJ, et al. TGF-beta1-induced PAI- 1 gene expression requires MEK activity and cell-to-substrate adhesion. J Cell Sci 2001;114:3905-3914. (Pubitemid 33094705)
54. Weis SM, Zimmerman SD, Shah M, et al. A role for decorin in the remodeling of myocardial infarction. Matrix Biol 2005;24:313-324. (Pubitemid 40853880)
55. Jarvelainen H, Puolakkainen P, Pakkanen S, et al. A role for decorin in cutaneous wound healing and angiogenesis. Wound Repair Regen 2006;14:443-452. (Pubitemid 44266601)
56. Schaefer L, Macakova K, Raslik I, et al. Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction. Am J Pathol 2002;160:1181-1191. (Pubitemid 34224603)
57. Williams KJ, Qiu G, Usui HK, et al. Decorin deficiency enhances progressive nephropathy in diabetic mice. Am J Pathol 2007;171: 1441-1450. (Pubitemid 350158306)
58. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331:1286-1292. (Pubitemid 24333194)
59. Flanders KC. Smad3 as a mediator of the fibrotic response. Int J Exp Pathol 2004;85:47-64. (Pubitemid 38703594)
60. Massague J. TGF-beta signal transduction. Annu Rev Biochem 1998;67:753-791.
61. Miyazono K, ten Dijke P, Heldin CH. TGF-beta signaling by Smad proteins. Adv Immunol 2000;75:115-157.
62. Latella G, Vetuschi A, Sferra R, et al. Targeted disruption of Smad3 confers resistance to the development of dimethylnitrosamineinduced hepatic fibrosis in mice. Liver Int 2009;29:997-1009.
63. Schnabl B, Kweon YO, Frederick JP, et al. The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology 2001;34:89-100. (Pubitemid 32591487)
64. Pannu J, Nakerakanti S, Smith E, et al. Transforming growth factor-beta receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways. J Biol Chem 2007;282: 10405-10413. (Pubitemid 47093454)
65. Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res 2009; 19:128-139.